A Phase 1 interventional study of Midazolam and LY3502970 in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in Singapore. Open to participants aged 21 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-26.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of this study is to determine the levels of study drug called LY3502970 in the blood stream when administered alone and in combination with cyclosporine in healthy participants. The study will also evaluate the safety and tolerability of LY3502970 in healthy participants. This study will last up to approximately 76 days for each participant.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Period 1: 200 micrograms (μg) midazolam administered as oral solution (5mg/5 mL solution ampoule) on Day -1 followed by 3 milligrams (mg) LY3502970 capsule given orally on Day 1.
Drug: Midazolam · Drug: LY3502970
Period 2: 2 -100 mg Cyclosporine capsules administered twice daily (BID) on Days 15 through 19; 3 mg LY3502970 given orally on Day 17; 200 μg Midazolam administered as oral solution on Days 16 and 19; Single oral dose 200 mg cyclosporine on Day 20.
Drug: Midazolam · Drug: LY3502970 · Drug: Cyclosporine
Administered orally.
Administered orally.
Administered orally.
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3502970
PK: AUC of LY3502970
Time frame: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, 96 hours postdose
PK: Maximum Observed Concentration (Cmax) of LY3502970
PK: Cmax of LY3502970
Time frame: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, 96 hours postdose
This is a 2-period single arm study with a washout period of at least 14 days between Period 1 and Period 2.
| Milestone | Midazolam + Cyclosporine + LY3502970 |
|---|---|
| Started | 32 |
| Received at least one dose of study drug | 31 |
| Completed | 25 |
| Not completed | 7 |
| Withdrew: Adverse event | 4 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Physician decision | 2 |
| Milestone | Midazolam + Cyclosporine + LY3502970 |
|---|---|
| Started | 25 |
| Completed | 21 |
| Not completed | 4 |
| Withdrew: Adverse event | 1 |
| Withdrew: Withdrawal by subject | 3 |
PK: AUC of LY3502970
| nanogram * hour per milliliter (ng*hr/mL | LY3502970 (Reference) | Cyclosporine + LY3502970 (Test) |
|---|---|---|
| Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3502970 | 332 ± 39 | 857 ± 51 |
PK: Cmax of LY3502970
| nanogram per milliliter (ng/mL) | LY3502970 (Reference) | Cyclosporine + LY3502970 (Test) |
|---|---|---|
| PK: Maximum Observed Concentration (Cmax) of LY3502970 | 13.9 ± 48 | 18.4 ± 36 |
Collected over Baseline up to 76 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 200 ug Midazolam | 0/31 (0%) | 0/31 (0%) | 4/31 (12.9%) |
| 3 mg LY3502970 (Reference) | 0/31 (0%) | 0/31 (0%) | 28/31 (90.3%) |
| 200 mg Cyclosporine BID + 200 ug Midazolam | 0/24 (0%) | 0/24 (0%) | 18/24 (75%) |
| 200 mg Cyclosporine BID + 3 mg LY3502970 (Test) | 0/24 (0%) | 0/24 (0%) | 22/24 (91.7%) |
| 200 mg Cyclosporine | 0/25 (0%) | 0/25 (0%) | 20/25 (80%) |
| Event | 200 ug Midazolam | 3 mg LY3502970 (Reference) | 200 mg Cyclosporine BID + 200 ug Midazolam | 200 mg Cyclosporine BID + 3 mg LY3502970 (Test) | 200 mg Cyclosporine |
|---|---|---|---|---|---|
| VomitingGastrointestinal disorders | 0/31 | 13/31 | 1/24 | 13/24 | 5/25 |
| Decreased appetiteMetabolism and nutrition disorders | 0/31 | 5/31 | 0/24 | 11/24 | 3/25 |
| Abdominal distensionGastrointestinal disorders | 1/31 | 11/31 | 0/24 | 10/24 | 1/25 |
| NauseaGastrointestinal disorders | 0/31 | 11/31 | 2/24 | 9/24 | 1/25 |
| Feeling hotGeneral disorders | 0/31 | 0/31 | 3/24 | 0/24 | 8/25 |
| Catheter site bruiseGeneral disorders | 0/31 | 5/31 | 4/24 | 0/24 | 5/25 |
| Catheter site swellingGeneral disorders | 0/31 | 0/31 | 4/24 | 1/24 | 2/25 |
| HeadacheNervous system disorders | 1/31 | 5/31 | 2/24 | 4/24 | 4/25 |
| DizzinessNervous system disorders | 0/31 | 5/31 | 1/24 | 2/24 | 0/25 |
| Catheter site phlebitisGeneral disorders | 0/31 | 1/31 | 1/24 | 3/24 | 4/25 |
All participants who received at least one dose of study drug.
| Age, Continuous(years) | Midazolam + Cyclosporine + LY3502970 |
|---|---|
| Mean | 41.3 ± 11.5 |
| Sex: Female, Male(Participants) | Midazolam + Cyclosporine + LY3502970 |
|---|---|
| Female | 4 |
| Male | 27 |
| Race (NIH/OMB)(Participants) | Midazolam + Cyclosporine + LY3502970 |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 31 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | Midazolam + Cyclosporine + LY3502970 |
|---|---|
| Singapore | 31 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2022 to primary completion in Jan 2023, 3 months.
Results were first posted in May 2026, 3 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Orforglipron